Search
Marzeptacog alfa (activated)
go.drugbank.com/drugs/DB15278InvestigationalMarzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects
Glutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Mixtures: Vista Advanced AREDS2 FormulaAtractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedAtractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Isa Knox Smart Bb Sun, Isa Knox Tervina Repair Foundation BbLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...
Dexketoprofen
go.drugbank.com/drugs/DB09214ApprovedInvestigationalWithdrawnDexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties .
Epitestosterone
go.drugbank.com/drugs/DB07768ExperimentalEpitestosterone is the 17-alpha isomer of testosterone, derived from pregnenolone via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose.
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Categories: Somatostatin Receptor AgonistsCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalSARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). … Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalSARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). … Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction